Improve Medical Instruments Co Altman Z-Score
The Altman Z-Score of Improve Medical Instruments Co (300030.SZ) as of Oct 29, 2026 is 4.57. In the previous year, Altman Z-Score was 2.58 — a change of 77.21% (higher).
Get this data via API
Financial Data API
Altman Z-Score
4.57
YoY
77.21%
Last updated:
The Improve Medical Instruments Co Altman Z-Score history
3 Years
10 Years
25 Years
Max
| YEAR | Altman Z-Score | YoY |
|---|---|---|
| 4.57 | +77.21% | |
| 2.58 | -3.79% | |
| 2.68 | +23.86% | |
| 2.17 | -17.35% | |
| 2.62 | -15.76% | |
| 3.11 | +8.68% | |
| 2.86 | +19.55% | |
| 2.39 | -4.07% | |
| 2.49 | -31.27% | |
| 3.63 | -1.39% | |
| 3.68 | -49.92% | |
| 7.35 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Improve Medical Instruments Co Stock analysis
Frequently Asked Questions about Improve Medical Instruments Co stock
Altman Z-Score of Improve Medical Instruments Co is 4.57 in 2025.
On Eulerpool you can find the complete historical development of Altman Z-Score Improve Medical Instruments Co since 2006 – with annual values, charts, and detailed analysis.
The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Improve Medical Instruments Co
All Key Metrics — Improve Medical Instruments Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth